Correlation of levetiracetam concentrations between serum and saliva

被引:46
作者
Grim, SA
Ryan, M
Miles, MV
Tang, PH
Strawsburg, RH
deGrauw, TJ
Fakhoury, TA
Baumann, RJ
机构
[1] Univ Kentucky, Chandler Med Ctr, Lexington, KY USA
[2] Cincinnati Childrens Hosp, Ctr Med, Cincinnati, OH USA
关键词
D O I
10.1097/00007691-200302000-00009
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Purpose: More than 100 drugs have been evaluated for salivary therapeutic drug monitoring since the 1970s. The most studied drugs are the anticonvulsants phenytoin, phenobarbital, and carbamazepine, demonstrating strong correlations between serum and saliva concentrations. No published data exist for levetiracetam (LEV) to the authors' knowledge. This study's objective is to determine the correlation between LEV serum and saliva concentrations. Methods: Investigators identified subjects seen in neurology clinics at the University of Kentucky. Patients were eligible if they agreed to participate in this study, were taking LEV for a minimum of 4 weeks, and if a serum LEV concentration had been ordered by their physician. Patients spit a minimum of 0.25 mL into a cup to obtain saliva samples. Blood samples were obtained by phlebotomy. Results: Serum and saliva LEV concentrations were determined via high performance liquid chromatography (HPLC) in two separate reference laboratories. Linear regression analysis was used to evaluate correlations. Serum and saliva samples were obtained from 40 patients (22 female, 18 male), ranging from 3 to 57 years of age. The mean +/- SD serum LEV concentration for reference laboratory A was significantly lower (P < 0.0001) than reference laboratory B, 23.6 +/- 13.8 mug/mL and 27.0 +/- 16.9 mug/mL, respectively. The mean +/- SD saliva to serum concentration fraction was also different for the two laboratories, i.e., 41.0% +/- 0.15% for lab A and 36.0% +/- 0.15% for lab B (P = 0.001). The correlation coefficients for the two laboratories were similar, 0.87 and 0.86 (both P < 0.0001) for labs A and B, respectively. Conclusion: A significant positive correlation exists between LEV saliva and serum concentrations. The ability to monitor LEV therapy using saliva may provide benefits that include facilitating sample collection and improving the quality of life for persons with epilepsy. Patients with poor venous access, such as children and elderly patients, and persons afraid of needles may particularly benefit from this method.
引用
收藏
页码:61 / 66
页数:6
相关论文
共 37 条
  • [1] ANAVEKAR SN, 1978, CLIN PHARMACOL THER, V24, P629
  • [2] USE OF SALIVA IN MONITORING CARBAMAZEPINE MEDICATION IN EPILEPTIC CHILDREN
    BARTELS, H
    OLDIGS, HD
    GUNTHER, E
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 1977, 126 (1-2) : 37 - 44
  • [3] Bauchner H, 1996, PEDIATRICS, V98, P861
  • [4] Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy
    Ben-Menachem, E
    Falter, T
    [J]. EPILEPSIA, 2000, 41 (10) : 1276 - 1283
  • [5] COMPARISON OF PLASMA AND SALIVA CONCENTRATIONS OF THE ACTIVE MONOHYDROXY METABOLITE OF OXCARBAZEPINE IN PATIENTS AT STEADY-STATE
    CARDOT, JM
    DEGEN, P
    FLESCH, G
    MENGE, P
    DIETERLE, W
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 1995, 16 (07) : 603 - 614
  • [6] FALLACIOUS RESULTS FROM MEASURING SALIVARY CARBAMAZEPINE CONCENTRATIONS
    DICKINSON, RG
    HOOPER, WD
    KING, AR
    EADIE, MJ
    [J]. THERAPEUTIC DRUG MONITORING, 1985, 7 (01) : 41 - 45
  • [7] SALIVA PHENOBARBITAL AND PHENYTOIN CONCENTRATIONS IN EPILEPTIC ADOLESCENTS
    FRIEDMAN, IM
    LITT, IF
    HENSON, R
    HOLTZMAN, D
    HALVERSON, D
    [J]. JOURNAL OF PEDIATRICS, 1981, 98 (04) : 645 - 647
  • [8] A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus
    Frucht, SJ
    Louis, ED
    Chuang, C
    Fahn, S
    [J]. NEUROLOGY, 2001, 57 (06) : 1112 - 1114
  • [9] Genton P, 2000, EPILEPTIC DISORD, V2, P209
  • [10] Levetiracetam for acute mania
    Goldberg, JF
    Burdick, KE
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (01) : 148 - 148